{"id":"pa32540","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal upset"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Dyspepsia"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"PA32540 combines acetaminophen with an NSAID in a single formulation to leverage synergistic analgesic effects while potentially reducing NSAID-related gastrointestinal toxicity through optimized dosing. The combination targets multiple pain pathways—acetaminophen via central COX inhibition and the NSAID via peripheral COX inhibition—to achieve greater efficacy at lower individual doses.","oneSentence":"PA32540 is a fixed-dose combination of acetaminophen and a nonsteroidal anti-inflammatory drug (NSAID) designed to provide enhanced pain relief with potentially improved gastrointestinal safety.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:50:53.021Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute pain management (Phase 3 development)"}]},"trialDetails":[{"nctId":"NCT00961350","phase":"PHASE3","title":"A Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers","status":"COMPLETED","sponsor":"POZEN","startDate":"2009-10","conditions":"Gastric Ulcer","enrollment":530},{"nctId":"NCT00960869","phase":"PHASE3","title":"Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers","status":"COMPLETED","sponsor":"POZEN","startDate":"2009-10","conditions":"Gastric Ulcer","enrollment":519},{"nctId":"NCT00995410","phase":"PHASE3","title":"Study to Evaluate the Long-Term Safety of PA32540 in Subjects Who Are at Risk for Developing Aspirin-Associated Gastric Ulcers","status":"COMPLETED","sponsor":"POZEN","startDate":"2009-10","conditions":"Aspirin-Associated Gastric Ulcers","enrollment":380},{"nctId":"NCT01557335","phase":"PHASE1","title":"A Study to Evaluate Platlet Aggregation of Clopidogrel, EC Aspirin 81 mg, EC Omeprazole 40 mg Compare to PA32540","status":"COMPLETED","sponsor":"POZEN","startDate":"2010-11","conditions":"Platelet Aggregation","enrollment":30},{"nctId":"NCT00700687","phase":"PHASE1","title":"Study Evaluating the Effect on Gastroduodenal Mucosa of PA32540, PA32540 and Celecoxib, and Aspirin With Celecoxib","status":"COMPLETED","sponsor":"POZEN","startDate":"2008-06","conditions":"Healthy","enrollment":90},{"nctId":"NCT00632086","phase":"PHASE1","title":"Evaluate Relative Bioavailability of PA32540 (Asa/Omeprazole), Its Aspirin Component, and Ecotrin® in Healthy Volunteers","status":"COMPLETED","sponsor":"POZEN","startDate":"2008-02","conditions":"Healthy","enrollment":36}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":12,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["YOSPRALA"],"phase":"phase_3","status":"active","brandName":"PA32540","genericName":"PA32540","companyName":"POZEN","companyId":"pozen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"PA32540 is a fixed-dose combination of acetaminophen and a nonsteroidal anti-inflammatory drug (NSAID) designed to provide enhanced pain relief with potentially improved gastrointestinal safety. Used for Acute pain management (Phase 3 development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}